SecBot SecBot

MYGN

MYRIAD GENETICS INC
Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. DE· CIK 0000899923 Biotech & Drug Discovery
$5.57 −0.09 (−1.59%)
Nov 16 4:00 PM ET · prev $5.66
Market cap
$544.8M
Small cap
Consensus
Hold
7% Buy or better · 14 analysts
Median target
$5.70
+2% · range $3.80–8.00
1 year
−16.4%
from $6.66 · Nov 17
30 days
+32.3%
from $4.21
52-week range
$2.86–7.91
−30% from high · low Jul 31
Avg volume 20D
3.23M
Oct 20 spike 24.00M
Short interest
8.44M
≈8.8% of shares · −9.0%
Days to cover
2.0
at average volume
Insider net
−$39.2K
1 buyer · 1 seller · since Mar 13
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 1 bearish · 1 bullish · 1 mixed · 8 neutral oldest → newest, height = score
Avg score ·High conf. 8/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $27.6K at an average $3.69. 1 insider sold $66.8K. Price is 51% above their cost.

  • InstitutionsMIXED

    Q3 2026: 25 added (0 new), 25 trimmed or exited.

  • AnalystsMIXED

    1 of 14 rate it Buy or better. Median target $5.70 (+2%).

  • Short sellersSTEADY

    Short interest −9.0% to 8.44M shares. 2.0 days to cover, ≈8.8% of shares.

  • TrendUPTREND

    16% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 30.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD15,924,022$68.6M
MACKENZIE FINANCIAL CORPADD2,499,354$10.8M
MARSHALL WACE, LLPADD2,072,548$8.9M
GEODE CAPITAL MANAGEMENT, LLCTRIM1,721,609$7.4M
Qube Research & Technologies LtdTRIM1,089,602$4.7M
DIMENSIONAL FUND ADVISORS LPTRIM784,445$3.4M
Jump Financial, LLCDOUBLED708,878$3.1M
BNP PARIBAS FINANCIAL MARKETSADD708,055$3.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Hold 7% rate it Buy or better
Strong Buy0Buy1Hold8Sell2Strong Sell3
12-month targets · 8 analysts

Price is inside the target range. Median implies +2%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 12, 2026Stephens & Co.
MAINTAIN
MAINTAINEqual-Weight
Nov 5, 2026TD Cowen
MAINTAIN
MAINTAINHold
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINMarket Perform
Oct 13, 2026TD Cowen
MAINTAIN
MAINTAINHold
Oct 2, 2026Craig-Hallum
MAINTAIN
MAINTAINBuy
Sep 9, 2026UBS
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$27.6K
bought · 1 insider
$66.8K
sold · 1 insider
+51.2%
vs their $3.69 cost
DateInsiderTypeValue
Nov 6, 2026
Verratti Mark
Chief Operating Officer
Nov 6, 2026
AWARD146,933 sh
Nov 6, 2026
Sikri Vishal
EVP, Commercial
Nov 6, 2026
AWARD53,236 sh
Nov 6, 2026
Solaiman Shereen
Chief People Officer
Nov 6, 2026
AWARD83,049 sh
Nov 6, 2026
Wheeler Benjamin Richard
Chief Financial Officer
Nov 6, 2026
AWARD121,379 sh
Nov 6, 2026
Fox Jennifer Lynne
Chief Legal & Corp Strategy
Nov 6, 2026
AWARD139,267 sh
Nov 6, 2026
Muzzey Dale
Chief Scientific Officer
Nov 6, 2026
AWARD92,632 sh
Nov 6, 2026
Jampa Raj
Chief Technology Officer
Nov 6, 2026
AWARD58,560 sh
Nov 1, 2026
Fox Jennifer Lynne
Chief Legal & Corp Strategy
Nov 1, 2026
AWARD39,370 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

39 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
8,435,005
shares short
-9.0%
vs prior settlement
2.0
days to cover
≈8.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 9, 2026 SEC
Myriad Genetics granted one-time retention stock options to three named executive officers (CFO, COO, CSO) totaling…
8-K · Impact 2/10
Nov 6, 2026 Insider
Verratti Mark was granted 146,933 shares
Chief Operating Officer
Nov 6, 2026 Insider
Sikri Vishal was granted 53,236 shares
EVP, Commercial
Nov 6, 2026 Insider
Solaiman Shereen was granted 83,049 shares
Chief People Officer
Nov 5, 2026 SEC
Myriad Genetics disclosed a cybersecurity incident on November 2, 2026, involving unauthorized access to its IT…
8-K · Impact 4/10
Nov 4, 2026 Earnings result
MYGN Q3 2026 Earnings: EPS $-0.11 (+46.1% vs est)
Sep 30, 2026 Inst.
BlackRock, Inc. · ADD
15,924,022 shares ($68.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 4, 2026
Earnings result
MYGN Q3 2026 Earnings: EPS $-0.11 (+46.1% vs est)
Nov 2, 2026
Press release
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad to participate in UBS Global Healthcare Conference, 2026 Stephens Investment Conference and 38th Annual Piper Sandler Healthcare Conference.
Oct 22, 2026
Press release
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic…
Oct 15, 2026
Earnings
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026...
Sep 16, 2026
Leadership
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

SecBot reports

13 filings · 3 press releases · 2 bullish · 2 bearish · 1 mixed · 8 neutral
All MYGN filing & press-release reports (16)